Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8985190 | 0.81 | NOTUM (0.36) | KDM4ERORCMEN1KMT2ACYP11B2 | |
| Hydrochloric Acid SCHEMBL8985242 | 0.80 | NOTUM (0.35) | KDM4ERORCMEN1KMT2ACYP11B2 | |
| SCHEMBL18365975 | 0.73 | CYP11B2 (0.39) | CYP11B2 | |
| SCHEMBL1702050 | 0.71 | ADRA1A (0.44) | KDM4EBRD4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL408207 | 0.68 | ATAD2 (0.36) | KDM4EBRD4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29852659 | 0.68 | LMNA (0.36) | KDM4EBRD4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31132468 | 0.68 | KDM4E (0.38) | KDM4EBRD4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18365979 | 0.67 | CYP19A1 (0.34) | IDO1CYP11B2 | |
| SCHEMBL791232 | 0.66 | BRD4 (0.46) | KDM4EBRD4SMN1; SMN2TP53 | |
| SCHEMBL17869779 | 0.66 | CYP11B2 (0.43) | KDM4EBRD4SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-5547961-A | USING TETRAHYDROIMIDAZOPYRIDINE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| US-5336679-A | Treatment of irritable bowel syndrome | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0532754-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | KDM4E 2393/4885BRD4 340/4885RORC 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.